Zur Suchmaske

Revitalizing pharmaceutical R&D: The value of real world evidence

Pharmaceutical companies face a major challenge that threatens reimbursement and value capture: The potential disruption from real world evidence (RWE) as a factor in evaluating new drugs.

Themen

Weiterlesen mit einem PwC Plus-Abonnement

  • qualitätsgesicherte Quellen
  • tägliche Updates
  • vollständige Filterfunktion von Artikeln
  • Verteilung via anpassbarem Alert

Jetzt 30 Tage kostenlos testen

Für den kostenfreien PwC Plus-Account registrieren

Loggen Sie sich ein, um den Artikel zu sehen

Mehr Informationen über PwC Plus

Zur Suchmaske
Zum Anfang
FAQ/Feedback

© 2017 - 2024 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.

This website contains copyright material of the IFRS® Foundation in respect of which all rights are reserved. Reproduced by PwC with the permission of the IFRS Foundation. No permission granted to third parties to reproduce or distribute. For full access to IFRS Standards and the work of the IFRS Foundation please visit www.ifrs.org.